Fig. 5From: The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatmentsSensitivity of vaccination strategy: comparison of 15-year relative prevalence reduction when vaccinating after treatment (A) versus vaccinating in the community under different parameter assumptions (B). The setting was with 50Â % initial chronic HCV prevalence among PWID, treating 20/1,000 PWID each year, and using a 30, 60 or 90Â % efficacious vaccine. HCV hepatitis C virus, PWID people who inject drugsBack to article page